FDA Approval of DOR/ISL Expands HIV Treatment Options Beyond INSTIs: Amy Colson, MD, MPH

Why It Matters

DOR/ISL expands therapeutic options for patients intolerant of INSTIs, simplifying regimens without sacrificing efficacy, which could improve adherence and outcomes in aging and diverse HIV populations.

Key Takeaways

• First FDA-approved 2‑drug regimen without INSTI or tenofovir
• Demonstrated non‑inferior viral suppression at 48 weeks versus standard regimens
• No impact on CD4 or lymphocyte counts at 0.25 mg islatravir dose
• Simplifies therapy for aging patients facing multimorbidity and polypharmacy
• Trial enrolled diverse cohort, enhancing relevance to underserved HIV populations

Pulse Analysis

The HIV treatment landscape has been dominated by INSTI‑based triple‑drug combos for over a decade, prized for potency but sometimes limited by neuropsychiatric side effects and drug‑drug interactions. As patients age and accumulate comorbidities, clinicians increasingly seek regimens that reduce pill burden and mitigate adverse events. Idvysno’s approval introduces a novel pathway: a two‑drug strategy that eliminates both an INSTI and tenofovir, offering a cleaner pharmacologic profile while maintaining the high barrier to resistance that modern HIV therapy demands.

Data from the pivotal 051 and 052 trials underpin the regimen’s credibility. Over 48 weeks, DOR/ISL achieved viral suppression rates statistically comparable to established three‑drug standards, with discontinuations due to adverse events mirroring control arms. Crucially, the low 0.25 mg islatravir dose avoided the lymphocyte reductions observed at higher exposures, preserving CD4 counts and overall immune health. The complementary mechanisms—doravirine’s non‑nucleoside reverse transcriptase inhibition and islatravir’s multi‑modal nucleoside action—provide robust antiviral activity while limiting resistance development, a key consideration for patients with prior treatment experience.

From a market perspective, DOR/ISL could reshape prescribing habits, especially for older patients juggling polypharmacy and for clinicians serving diverse, often underserved communities. The trial’s enrollment of over 30% Black and 15‑23% Latino participants enhances confidence in its generalizability. While insurance coverage and drug pricing will dictate real‑world uptake, the regimen’s simplicity and favorable safety profile position it as a compelling option to improve adherence, reduce long‑term toxicity, and ultimately advance the goal of sustained viral suppression across the HIV continuum.